AIM: To assess the refractive and functional outcomes of a novel trifocal intraocular lens (IOL) with smooth micro phase technology. METHODS: This prospective, single-arm, single-center, observational study included patients who underwent cataract surgery with the implantation of the AT ELANA 841P (Carl Zeiss Meditec, Berlin, Germany) IOL. Visual acuity (VA) at distance, intermediate, and near were evaluated 1- and 3-month postop as well as refractive outcomes. Monocular and binocular defocus curve, binocular contrast sensitivity (M&S® Technologies) and patient satisfaction with the Catquest-9SF questionnaire were measured at 3-month postop. RESULTS: In total, 46 eyes (23 patients) were bilaterally implanted with the IOL. Mean patient age was 59.86±5.55y. At 1-month postop, monocular corrected VA for distance, intermediate, and near were -0.15±0.09, 0.11±0.10, and 0.15±0.12 logMAR, respectively. These outcomes remained stable at the 3-month follow-up (P>0.05). Spherical equivalent (SE) at 1- and 3-month postop remained stable (P>0.05). Following surgery, 91% of the eyes at 1mo and 95% of the eyes at 3mo were within ±0.5 D of SE. Monocular defocus curve showed that the lens can be categorized as a steep transition IOL. The contrast sensitivity function revealed high values at low spatial frequencies and decreased values at high spatial frequencies. The results of the Catquest-9SF questionnaire showed that all patients were fairly or very satisfied with their vision after surgery. CONCLUSION: The AT ELANA 841P IOL offers excellent visual outcomes across distance, intermediate, and near ranges, along with satisfactory contrast sensitivity. Additionally, the lens is associated with high patient satisfaction and minimal visual difficulties during daily activities.